Kim, Hakhyun
Han, Jang Hee
Kim, Hyosil
Kim, Minjee
Jo, Seung-il
Lee, NaKyoung
Cha, Seungbin
Oh, Myung Joon
Choi, GaWon
Kim, Hyun Seok
Funding for this research was provided by:
National Research Foundation of Korea (2019H1A2A1075632, 2023R1A2C2003586)
Korea Health Industry Development Institute (HI14C1324)
Yonsei University College of Medicine (6-2021-0194)
Article History
Received: 1 August 2023
Accepted: 25 March 2024
First Online: 28 March 2024
Competing interests
: H.S.K. is the founder, chief scientific officer, and shareholder of Checkmate Therapeutics Inc. The other authors have no competing or financial conflicts of interest to declare.